Current filters:


Popular Filters

1970 to 1994 of 2442 results

QPS buys majority of Austria's largest independent CRO


In a second European acquisition, USA-based QPS, a full-service GLP/GCP-compliant contract research organization,…

BiotechnologyJSW Life SciencesMarkets & MarketingPharmaceuticalQPS HoldingsResearch

Gilead's Stribild, formerly "Quad," gets FDA nod


The US Food and Drug Administration has approved US biotech firm Gilead Sciences' (Nasdaq: GILD) Stribild…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaQuadRegulationStribild

Pharmaceutical sales rep access reducing most among oncologists in USA


As more pharmaceutical companies prepare to bring new oncology drugs to market, their sales representatives…

BiotechnologyManagementMarkets & MarketingNorth AmericaOncologyPharmaceutical

FDA calls on Genzyme to re-file Lemtrada sBLA


French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received…

BayerBiotechnologyGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Synergy Pharma gains rights to shingles drug from Bristol-Myers


US biopharma firm Synergy Pharmaceuticals (Nasdaq: SGYP) has signed an asset purchase agreement with…

Anti-viralsBiotechnologyBristol-Myers SquibbFV-100Mergers & AcquisitionsSynergy Pharmaceuticals

Cancer treatments top breakthrough medicines list, Australian study finds


A cure for cancer is still to be found but more new treatments have been approved for Australians with…

Asia-PacificBiotechnologyHealthcareMarkets & MarketingPharmaceuticalResearch

Bristol-Myers drops hep C pill on patient safety issues


US drug major Bristol-Myers Squibb (NYSE: BMY) has discontinued development of BMS-986094 (formerly known…

Anti-viralsBiotechnologyBMS-986094Bristol-Myers SquibbPharmaceuticalRegulationResearch

Pharming first-half 2012 net loss nearly doubles


Netherlands-based biotech company Pharming (NYSE Euronext: PHARM), which recently revealed that it is…


Gilead abandons development of PAH drug cicletanine


US biotech firm Gilead Sciences (Nasdaq: GILD), the world leader in HIV/AIDS drugs, has discontinued…

BiotechnologycicletanineGilead SciencesRare diseasesResearchRespiratory and Pulmonary

Australia's BTWG opens discussion on cuts to R&D Tax Incentive


The Australian Business Tax Working Group (BTWG) has issued a discussion paper, which includes amongst…


EMA accepts Dynavax' filing for hep B drug Heplisav


US biotech firm Dynavax Technologies (Nasdaq: DVAX) revealed yesterday that the European Medicines Agency…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Study confirms economic viability of orphan drugs positioned for unmet medical needs


Orphan drugs achieve blockbuster status in 2011 and generate over $50 billion in revenue, according to…

BiotechnologyFinancialMarkets & MarketingPharmaceutical

NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost


The latest and final guidance from the UK's drug watchdog the National Institute for Health and Clinical…


Pharmacyclics gets second $50 million milestone from Janssen


California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Dainippon Sumitomo to set up DSP Cancer Institute


Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says it plans to establish a new organization…

BiotechnologyDainippon Sumitomo PharmaManagementOncologyPharmaceuticalResearch

New entrants from Roche and Novartis will drive breast cancer market


Through 2021, the uptake of three new market entrants, Roche (ROG: SIX)/Genentech's Perjeta (pertuzumab)…

AfinitorBiotechnologyMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRoche

AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status


In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

Idenix plunges as FDA puts clinical hold on hepatitis C drug candidate


US biotech firm Idenix Pharmaceuticals (Nasdaq: IDIX) saw its shares tank 29% to $5.91 in morning trading…

Anti-viralsBiotechnologyIdenix PharmaceuticalsIDX184North AmericaPharmaceuticalRegulationResearch

TG Thera in up to $250 million deal with Rhizen


US development stage company TG Therapeutics (GTX:OTC B) has entered into an exclusive global agreement…

BiotechnologyImmunologicalsLicensingOncologyRhizen PharmaceuticalsTG TherapeuticsTGR-1202

1970 to 1994 of 2442 results

Back to top